Skip Navigation


JAC Advance Access originally published online on May 14, 2008
Journal of Antimicrobial Chemotherapy 2008 62(2):234-245; doi:10.1093/jac/dkn191
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/2/234    most recent
dkn191v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pérez-Molina, J. A.
Right arrow Articles by Moreno, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pérez-Molina, J. A.
Right arrow Articles by Moreno, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Reviews

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy

José A. Pérez-Molina1,*, Pere Domingo2, Esteban Martínez3 and Santiago Moreno4

1 Tropical Medicine and Clinical Parasitology Unit, Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain 2 Infectious Diseases Unit, Hospital de la Santa Creu i San Pau, Universitat Autònoma de Barcelona, Barcelona, Spain 3 Infectious Diseases Unit, Hospital Clínic, University of Barcelona-IDIBAPS, Barcelona, Spain 4 Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

* Corresponding author. Tel: +34-913368108; Fax: +34 913368792; E-mail: japerezm.hrc{at}salud.madrid.org

Highly active antiretroviral therapy plays a central role in the development of lipodystrophy syndrome, which may affect up to 50% of patients depending on the diagnostic criteria used. Most protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs) are involved in body fat changes and associated metabolic disturbances. In contrast, non-NRTIs have not been directly related to the onset of this syndrome. One of the most widely used methods to evaluate body fat changes is dual-energy X-ray absorptiometry (DEXA), which can detect differences in the distribution of body fat in patients with and without lipodystrophy. New information from a randomized open-label clinical trial suggests that efavirenz could have greater potential for causing lipoatrophy than lopinavir+ritonavir. This paper examines the impact of efavirenz on adipose tissue and body fat composition in order to evaluate whether this drug plays a role in the development of lipodystrophy. We have focused on the evidence obtained from comparative randomized clinical trials that use an objective measurement of fat distribution, such as DEXA. We analysed available in vitro data and evidence from non-comparative clinical trials.

Keywords: lipodystrophy , lopinavir , DEXA scan , antiretroviral drugs , HAART


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.